{"prompt": "['6.0', 'ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS', 'AE monitoring and reporting is a routine part of every clinical trial. The following list of', 'AEs (Section 6.1) and the characteristics of an observed AE (Section 6.2) will determine', 'whether the event requires expedited reporting in addition to routine reporting (via', 'Advantage eClinical). All adverse event reporting will be conducted via Advantage', 'eClinical for this protocol.', 'The CTEP Version 5.0 of the NCI Common Terminology Criteria for Adverse Events', '(CTCAE) will be utilized for AE reporting. The CTEP Version 5.0 of the CTCAE is', 'identified and located on the CTEP website at', 'http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.', 'All appropriate treatment areas should have access to a copy of the CTEP Version 5.0 of', 'CTCAE.', '6.1', 'Adverse Events and Potential Risks Lists', 'For full details, consult the package insert.', 'Table 6-A: Adverse Event List for Vincristine', 'Rare or Serious Side Effects', 'Frequently Occurring Side Effects', 'Autonomic neuropathy', 'Nausea and vomiting (minimal)', 'Bronchospasm', 'Alopecia (reversible)', 'Seizure', 'Constipation', 'Insomnia', 'Myelosuppression (mild)', 'Cranial Neuropathy', 'Musculoskeletal pain', 'SIADH', 'Peripheral Neuropathy', 'Chemical Phlebitis', 'Acute Hypersensitivity reactions', 'Hypertension', 'Table 6-B: Adverse Event List for Bleomycin', 'Rare or Serious Side Effects', 'Frequently Occurring Side Effects', 'Hypotension', 'Nausea and vomiting (minimal)', 'Pleuropericarditis', 'Alopecia (reversible)', 'Radiation recall reaction', 'Nail changes', 'Disseminated intravascular', 'Pruritus', 'coagulation', 'Hemolytic uremic syndrome', 'Skin hyperpigmentation', 'Pneumonitis', 'Mucositis (30%)', 'Fever, chills', '6.2', 'Classification of AEs by Severity and Relationship to Treatment Administration', '6.2.1 Adverse event: Any unfavorable and unintended sign (including an abnormal', 'laboratory finding), symptom, or disease temporally associated with the use of a', 'medical treatment or procedure regardless of whether it is considered related to the', 'medical treatment or procedure (attribution of unrelated, unlikely, possible,', 'AMC-S007 (Version 2.0) 20MAR2018', '26', 'NCI Version Date 20MAR2018']['probable, or definite).', 'This includes the following:', 'AEs not previously observed in the participant that emerge during the protocol-', 'specified AE reporting period, including signs or symptoms associated with the', 'study disease that were not present prior to study entry.', 'Complications that occur as a result of protocol interventions.', 'Preexisting medical conditions (other than the condition being studied) judged', 'by the investigator to have worsened in severity or frequency, or changed in', 'character during the protocol-specified AE reporting period.', \"AEs will be followed for the participant's medical care until resolved to the baseline\", 'condition or protocol completion; for chronic conditions, resolution may occur', 'when the AE is stable with appropriate medical management.', '6.2.2', 'Life-threatening adverse event: Any AE that places the participant or participant,', 'in view of the Investigator, at immediate risk of death from the reaction.', '6.2.3', 'Serious adverse event (SAE): Any AE occurring at any dose that results in any of', 'the following outcomes: Death, a life-threatening AE, inpatient hospitalization or', 'prolongation of existing hospitalization, a persistent or significant disability/', 'incapacity, or a congenital anomaly/birth defect. Important medical events that may', 'not result in death, be life-threatening, or require hospitalization may be considered', 'serious when, based upon appropriate medical judgment, they may jeopardize the', 'participant and may require medical or surgical intervention to prevent one of the', 'outcomes listed in this definition.', '6.2.4', 'Hospitalization: hospitalization for expedited AE reporting purposes is defined as', 'an inpatient hospital stay equal to or greater than 24 hours. Hospitalization is used', 'as an indicator of the seriousness of the AE and should ONLY be used for situations', 'where the AE truly fits this definition and NOT for hospitalizations associated with', 'less serious events. (e.g., a hospital visit where a patient is admitted for observation', 'or minor treatment such as, hydration and released in less than 24 hours).', 'Prolongation of hospitalization is defined as an extension of current hospitalization', 'equal to or greater than 24 hours.', 'Please note for hospitalization - All hospitalizations (or prolongation of existing', 'hospitalization) for medical events equivalent to CTCAE Grade 3, 4, 5 must be', 'reported regardless of the requirements for Phase of study, expected or unexpected,', 'and attribution. For example, do not report an admission for pharmacokinetic', 'sampling, but do report an admission for a myocardial infarction.', '6.2.5 Toxicity: Toxicity is a term NOT clearly defined by regulatory organizations.', 'Toxicity has been described as an AE that has an attribution of possibly, probably', 'or definitely related to investigational treatment. To minimize confusion the NCI', 'would recommend that the term toxicity NOT be utilized for AE reporting', 'purposes. The CTCAE continues to use the term \"toxicity\\' because of familiarity.', '6.2.6 Unexpected adverse event: Any AE that is not listed in available sources including', 'AMC-S007 (Version 2.0) 20MAR2018', '27', 'NCI Version Date 20MAR2018'][\"the package insert, the Investigator's Brochure, or the protocol, or is not consistent\", 'with the severity or specificity of the risk information described in the available', 'sources, or is not consistent with the severity or specificity of the risk information', 'described in the available sources.', '6.2.7 CTEP Adverse Event Reporting System (CTEP-AERS): An electronic system for', 'expedited submission of AE reports. A SAE reporting form in Advantage eClinical', 'will be used in lieu of CTEP-AERS for expedited AE reporting on this trial.', '6.2.8 Attribution: An assessment of the relationship between the AE and the medical', 'intervention. The CTCAE does not define an AE as necessarily \"caused by a', \"therapeutic intervention.' After naming and grading the event, the clinical\", 'investigator must assign an attribution to the AE using the following attribution', 'categories:', 'Table 6-C: Attribution', 'RELATIONSHIP', 'ATTRIBUTION', 'DESCRIPTION', 'Unrelated to', 'Unrelated', 'The AE is clearly NOT related to', 'treatment/intervention', 'the intervention', 'Unlikely', 'The AE is doubtfully related to', 'the intervention', 'Related to', 'Possible', 'The AE may be related to the', 'treatment/intervention', 'intervention', 'Probable', 'The AE is likely related to the', 'intervention', 'Definite', 'The AE is clearly related to the', 'intervention', 'NOTE: AEs listed as \"possibly, probably, or definitely\\' related to the', \"treatment/intervention are considered to have a suspected 'reasonable causal\", \"relationship' to the treatment/intervention (ICH E2A). For routine adverse event\", 'reporting purposes on this protocol, \"attribution\" defines the relationship between', 'the adverse event and the treatment/intervention.', '6.3', 'Expedited Adverse Event Reporting', '6.3.1 Expedited AE reporting for this study must use Advantage eClinical. The reporting', 'procedures to be followed are presented in this section and will align with the', 'principles for SAE reporting in the \"CTEP, NCI Guidelines: Adverse Event', 'Reporting Requirements,\" which can be downloaded from the CTEP home page', 'http://ctep.cancer.gov). These requirements are briefly outlined below (Section', '6.3.3).', 'A 24-hour notification is to be made to the AMC ODMC by telephone at +1 301-', '251-1161, only when Internet connectivity is disrupted. Once Internet connectivity', 'is restored, a 24-hour notification phoned in must be entered electronically into', 'Advantage eClinical by the original submitter at the site.', 'AMC-S007 (Version 2.0) 20MAR2018', '28', 'NCI Version Date 20MAR2018']", "completion": ""}